Modification of concentration-response curves to inhaled methacholine after the pollen season in subjects with pollen induced rhinitis

L Prieto, M López, J M Bertó, A Peris

Abstract

Background – The effect of cessation of exposure to pollen on the concentration-response curves to inhaled methacholine was investigated.

Methods – Methacholine inhalation challenges (up to 200 mg/ml) were performed in 13 non-asthmatic patients with grass and/or Parietaria pollen-induced rhinitis during the pollen season, and one and four months after it. Concentration-response curves were characterised by their PC20 position, and plateau.

Results – Geometric mean methacholine PC20 increased from 6.4 mg/ml during the pollen season to 28.2 mg/ml and 54.9 mg/ml one and four months after the end of season, respectively. The mean (SE) level of the plateau decreased from 30.5 (4.3)% in the pollen season to 23.3 (3.7)% and 20.1 (3.3)% one and four months after the end of pollen season, respectively. Although the methacholine concentration that produced 50% of the maximal response increased from 2.9 mg/ml to 4.3 mg/ml and 6.0 mg/ml, the differences were not significant.

Conclusions – In non-asthmatic patients with pollen-induced rhinitis cessation of exposure to pollen is associated with significant modifications in the methacholine threshold value and level of plateau, and with a small shift in the concentration-response curves to the right.

(Thorax 1994;49:711–713)

Previous studies in non-asthmatic subjects with allergic rhinitis have shown decrements in the provocative concentration of methacholine producing a 20% fall in FEV1 (PC20) related to natural allergen exposure.1 Other features of the dose-response curve, such as the position and level of plateau, may also be important in characterising the response to methacholine.2 We have therefore examined the effect of cessation of exposure to pollen on PC20 position, and the maximal response of concentration-response curves to methacholine in non-asthmatic patients with pollen sensitive allergic rhinitis.

Methods

Thirteen non-smoking patients (eight men; mean age 38 (range 22–59) years) with seasonal allergic rhinitis were studied. Criteria for inclusion were age 18 years or over; a positive skin prick test (weal diameter ≥3 mm compared with negative control) to grass and/or Parietaria pollens; no skin sensitisation to other allergens (olive, house dust mites, Alternaria, Aspergillus, Neurospora, Penicillium, Cladosporium, and cat and dog dander); no previous history of dyspnoea, cough, wheeze or exercise-induced asthma; no respiratory infections during the four weeks before each methacholine challenge.

Three methacholine inhalation challenges were performed: (1) in the middle of the grass and Parietaria pollen season; (2) one month after the end of the pollen season; and (3) four months after the end of the pollen season.

Each patient was required to have an FEV1 (three measurements that agreed within 5%) of at least 80% of the predicted value.3 Spirometric testing was performed on a dry rolling seal spirometer (Model PFT Horizon System Two; Sensormedics, California, USA). Anti-histamines were withheld for at least 72 hours. No other medication was taken during the study except at the peak of symptoms where intranasal beclomethasone dipropionate or budesonide was used by one and two subjects, respectively.

Methacholine challenge tests4 were performed with a Hudson 1720 nebuliser (Tecmeca, California, USA). The mean (SD) output was 0.198 (0.017) ml/min. The nebuliser was connected directly to a mouthpiece and the aerosol was inhaled through the mouth by tidal breathing for two minutes. Phosphate buffered saline (PBS) was inhaled first, followed at intervals of 3–5–4 minutes by twofold increasing concentrations of methacholine (Sigma; St Louis, Missouri, USA) from 0.39 to 200 mg/ml. FEV1 was measured 60–90 seconds after each inhalation. The challenge was extended until the FEV1 fell more than 50% from the post PBS value or the highest concentration of methacholine was reached.

Concentration-response curves were characterised by their PC20 position (EC50), and maximal response plateau. The PC20 and EC50 (concentration of methacholine producing 50% of the maximal response) were obtained by linear interpolation.
A plateau response was considered to be present when, for three or more of the highest concentrations of methacholine, the FEV₁ did not change by more than 5%. The level of the maximal response was obtained by averaging the data points on the plateau.³

Grass and *Parietaria* pollen counts were recorded daily with a Burkard spore trap (Burkard, Herts, UK) and expressed as the mean count/m³ of air each week.

The study was approved by the hospital medical ethics committee and all patients gave informed consent.

**STATISTICAL ANALYSIS**

All PC₂⁰ and EC₅₀ values were log transformed before analysis and PC₂⁰ values > 200 mg/ml were assigned to 200. In two subjects who showed FEV₁ falls > 50% without evidence of plateau during the pollen season the plateau levels were assigned as the percentage decline in FEV₁ at the end of the protocol.

The results of prechallenge FEV₁, PC₂⁰ and plateau level in each period were compared by analysis of variance of repeated measurements. Data are mean (SE) unless otherwise stated; p values <0.5 are considered significant.

**Results**

Weekly grass pollen counts between 35 and 268 grains/m³ were recorded from May to July, and weekly *Parietaria* pollen counts between 145 and 327 grains/m³ were recorded from the end of April to the beginning of August.

Baseline FEV₁ values during the pollen season, one month, and four months afterwards were 3/7 (0-3/1), 3/7 (0-3/1), and 3/6 (0-3/1), respectively. Two subjects (table) had PC₂⁰ values > 200 mg/ml throughout the three periods. In the remaining 11 subjects the geometric mean methacholine PC₂⁰ increased significantly both one and four months after the pollen season. In subjects with no censored values in at least one challenge PC₂⁰ values one and four months after the pollen season were 2-1 (0-7) and 3-4 (0-7) doubling concentrations higher than PC₂⁰ values during the pollen season. PC₂⁰ values four months after the pollen season were 1-5 (0-6) doubling concentrations higher than PC₂⁰ values one month after the season.

The level of the maximal response decreased significantly after the pollen season, but the geometric mean (range) EC₅₀ increased from 2-9 (0-8-12-4) mg/ml during the pollen season to 4-3 (1-3-11-9) mg/ml and 6-0 (0-8-28-9) mg/ml one and four months after it.

**Discussion**

The results of this study confirm that in non-asthmatic patients with pollen-induced rhinitis the level of exposure to pollen is associated with a significant increase in methacholine PC₂⁰, a decrease in the level of plateau, and a small shift in the concentration-response curves to the right.

The baseline FEV₁ values in each period did not differ, and patients were sensitised to grass and/or *Parietaria* pollens but did not show skin sensitisation to other allergens. Nasal corticosteroids may have decreased PC₂⁰ values during the seasonal period in three patients,⁶ but this would have resulted in a smaller change in PC₂⁰ between seasonal and post-seasonal periods in these subjects. We can therefore reasonably attribute changes in airway responsiveness to natural exposure to pollens.

Boulet et al⁵ showed that, in subjects with hay fever, natural pollen exposure significantly increased airway responsiveness (reduction of PC₂⁰) to methacholine and our results are in agreement with these observations. However, estimation of change in PC₂⁰ in non-asthmatic patients with allergic rhinitis is complicated because most subjects have PC₂⁰ values above the upper limit of measurement (seven of our 13 patients) and repeated measures provide no estimate of change. We have attempted to minimise the effect of censored values by including subjects in whom it was possible to obtain a measurement of PC₂⁰ in at least one challenge.

To accurately define the position of the concentration-response with respect to the x axis a complete concentration-response curve must be performed.⁴ A plateau response must therefore be achieved so that an EC₅₀ value can be assigned. To our knowledge this is the first study in which the effect of natural allergenic exposure on the plateau in response to methacholine has been investigated. Our results show that the level of the plateau decreases after the pollen season. Although a shift in the concentration-response curve to the right (increased EC₅₀) was detected after the pollen season, this change was not significant.

Boonsawat et al⁶ observed that allergen inhalation in the laboratory increased the maximal response to methacholine in atopic sub-

---

**Table 1:** PC₂⁰ and plateau values during the pollen season and one and four months after

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Pollen season</th>
<th>Four months after</th>
<th>Pollen season</th>
<th>Four months after</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>One month after</td>
<td>Four months after</td>
<td>One month after</td>
<td>Four months after</td>
</tr>
<tr>
<td>1</td>
<td>200</td>
<td>200</td>
<td>9.5</td>
<td>7.2</td>
</tr>
<tr>
<td>2</td>
<td>2-9</td>
<td>8-1</td>
<td>38-0</td>
<td>33-7</td>
</tr>
<tr>
<td>3</td>
<td>1-1</td>
<td>2-4</td>
<td>57-3</td>
<td>46-6</td>
</tr>
<tr>
<td>4</td>
<td>200</td>
<td>200</td>
<td>8-9</td>
<td>9-7</td>
</tr>
<tr>
<td>5</td>
<td>1-6</td>
<td>200</td>
<td>29-6</td>
<td>12-2</td>
</tr>
<tr>
<td>6</td>
<td>200</td>
<td>200</td>
<td>16-1</td>
<td>23-6</td>
</tr>
<tr>
<td>7</td>
<td>10-4</td>
<td>200</td>
<td>23-5</td>
<td>18-3</td>
</tr>
<tr>
<td>8</td>
<td>100-0</td>
<td>200</td>
<td>18-6</td>
<td>14-8</td>
</tr>
<tr>
<td>9</td>
<td>4-4</td>
<td>5-2</td>
<td>30-7</td>
<td>23-6</td>
</tr>
<tr>
<td>10</td>
<td>1-2</td>
<td>3-8</td>
<td>43-0</td>
<td>32-0</td>
</tr>
<tr>
<td>11</td>
<td>25-7</td>
<td>200</td>
<td>62-9</td>
<td>8-8</td>
</tr>
<tr>
<td>12</td>
<td>1-3</td>
<td>9-9</td>
<td>50-6f</td>
<td>29-1</td>
</tr>
<tr>
<td>13</td>
<td>4-8</td>
<td>3-3</td>
<td>46-0</td>
<td>45-0</td>
</tr>
</tbody>
</table>

GM = 6-4 28-2* 54-0**

PC₂⁰ = provocative concentration of methacholine producing a 20% fall in FEV₁; GM = geometric mean in 11 subjects in whom it was possible to obtain a measurement of PC₂⁰ in at least one challenge.

*p <0.05; **p <0.01.

* Plateau not detected.
Adventitia

A system is said to be chaotic in a scientific sense when the initial conditions of that system cannot be defined. A system under these conditions will appear to obey physical and chemical laws during short term observations but, due to this initial uncertainty, the ultimate manifestations of manipulations of the system cannot be predicted with accuracy. The human body is such a system. Under most, if not all, clinical conditions it is impossible to describe with the necessary accuracy the initial state of health of the body prior to the onset of a disease process. Most studies, no matter how rigid the inclusion and exclusion criteria are, must therefore contain a random sampling of patients whose outward appearance may appear similar but whose initial conditions may be very different. The implications of this may be very far reaching.

Cellular and laboratory animal preparations have better potential for establishing more uniform initial biological conditions than clinical human experimentation. As a result it is more likely that these experiments would demonstrate treatment benefits since there are fewer outside influences on these more simple systems to effect outcome – that is, there is less chaos present. This in part may explain the disparate results seen in some cellular and animal models of treatment regimes when applied to human populations. However, they do represent the necessary first steps in establishing efficacy of novel therapies and, in fact, may eventually be used to help establish the minimal requirements necessary for truly matching the initial conditions of subjects undergoing human experimentation.

Chaos presents many difficult challenges for the clinical researcher. Under most circumstances the overt manifestations of a disease are preceded by a non-specific prodrome. At the time a diagnosis is established, therefore, the biological system has undergone numerous interactions which may vary immensely from subject to subject. The threshold for an individual to present for treatment varies considerably, making it difficult consistently to manipulate the system at the same time in the course of a disease. The consequence of this is to increase the chaos of the biological system. As the system deviates from its resting state in the course of these reactions, it may reach a point where the system can no longer be manipulated by the planned intervention. If enough subjects in a clinical study reach this point the intervention may be perceived from a statistical standpoint to have no benefit – that is, a false negative result.

Earlier identification of a potential subject with the specific clinical entity to be studied, accompanied by the exclusion or statistical separation of patients found later in the course of the disease, should in part reduce the effect of chaos on the outcome of the intervention. Much work is currently being conducted in this area and new earlier markers for ARDS and sepsis are presently being evaluated. Additional work needs to be done to determine how better to match the initial conditions of patients entered into a study. The relative importance of all the potential influences of other organ system deficits on outcomes needs to be determined, such as the patient’s nutritional state, recent and remote infectious disease history, and medication history. Finally, the use of empiricism may be required until the above information is available. Under these constraints investigators may be forced to apply a proposed intervention to a large initial group of patients in whom an exhaustive database has been obtained. A detailed statistical evaluation might then demonstrate a subgroup of patients which appeared to have benefited from the intervention. The final step would be to apply the therapy again to this identified subgroup of patients in a randomised, prospective study which should then ultimately answer the question of efficacy. Although this could increase the cost and potentially slow down the process of clinical research, it would result in studies less confounded by chaos. The data from these studies would be less tainted with false positive and false negative results.

ERIC H GLUCK

Contributions to this column are encouraged (maximum 600 words), otherwise the column will close – SGS
Modification of concentration-response curves to inhaled methacholine after the pollen season in subjects with pollen induced rhinitis.

L Prieto, M López, J M Bertó and A Peris

Thorax 1994 49: 711-713
doi: 10.1136/thx.49.7.711

Updated information and services can be found at:
http://thorax.bmj.com/content/49/7/711

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/